



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

ALMAC DIAGNOSTICS MULTI YEAR LICENSE AGREEMENT WITH GENEGO

St. Joseph, Michigan, December 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, announced today that Almac Diagnostics has licensed their flagship data mining suite, MetaCore.

The multiple-year agreement will allow Almac Diagnostics' scientists in the UK and US to use MetaCore in the development of novel microarray-based products for the diagnosis and treatment of cancer. Almac Diagnostics' Genomic Services division that delivers comprehensive genomic services to academic, biotech and pharmaceutical customers will also use Metacore.

Almac values the completeness and quality of content coverage in MetaCore from signaling ligands to core metabolic pathways, its intuitive interface and comprehensive automated analysis workflows.

“We compared several platforms before we finally decided on GeneGo. MetaCore has broad and deep, high quality content coverage, which was important to us. Furthermore its ability to work with mixed ID's is critical for our internal R&D work and service offerings based on our unique **DSA**TM (patent pending) research tools” said Dr Vitali Proutski, Bioinformatics Manager at Almac Diagnostics. “We were also very impressed by GeneGo's responsiveness and strong customer support which we feel is vital in relationships with our partners.”

“We are very pleased to welcome Almac Diagnostics as a new GeneGo customer. Our experience with them during the thorough evaluation was very positive, with constant communication between Almac Diagnostics and GeneGo scientists” said Julie Bryant, Vice President of Business Development at GeneGo. “Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscoveryTM platform allows an integration and expert analysis of different

kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.1™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.

About Almac Diagnostics

Almac Diagnostics develops, markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product.

Almac Diagnostics has two divisions:

The *Genomic Services* division provides all inclusive gene expression, SNP and bioinformatics services to academia, biotech and pharmaceutical companies. These services include analysis on our unique **DSA**™ research tools, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorized Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services.

The *Research & Development Division* develops, using proprietary **DSA**™ research tools, new tests that will change the way cancers are managed in the future. These proprietary arrays provide unique information for individual cancer types and represent a stable, long-term platform for the development of clinical diagnostics.

www.almacgroup.com